Finance

Lists
SPRB:NASDAQ
Spruce Biosciences, Inc
$43.31
+0.98%
(+0.42) 1D
$43.31
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SPRB...
Open
$42.94
High
$43.38
Low
$41.41
Mkt. cap
124.47M
Avg. vol.
76.32K
Volume
38.86K
52-wk high
$127.90
52-wk low
$38.06
EPS
-$35.41
Beta
3.58
Shares outstanding
2.87M
No. of employees
25
Open
$42.94
High
$43.38
Low
$41.41
Mkt. cap
124.47M
Avg. vol.
76.32K
Volume
38.86K
52-wk high
$127.90
52-wk low
$38.06
EPS
-$35.41
Beta
3.58
Shares outstanding
2.87M
No. of employees
25
News stories
From web sources and news partners
About Spruce Biosciences, Inc
CEO-
Employees25
Founded2014
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 6 analysts giving stock ratings to SPRB in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for SPRB in the last 3 months.
Highest
Current $43.31
$230.00 (+431.06%)
Average
$155.50 (+259.04%)
Lowest
$104.00 (+140.13%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$150.00
+246.3%
11/13/2026
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
$160.00
+269.4%
11/10/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$230.00
+431.1%
11/10/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$140.00
+223.3%
09/30/2026
Daniel Brims
Lake Street
Buy
Initiated
$149.00
+244%
09/17/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$230.00
+431.1%
08/25/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$104.00
+140.1%
08/17/2026
Catherine Novack
JonesTrading
Buy
Initiated
$135.00
+211.7%
06/08/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$120.00
+177.1%
05/15/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$150.00
+246.3%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-1.80M
7.58M
12.16M
18.13M
Cost of revenue
-1.80M
7.58M
12.16M
18.13M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.00M
4.41M
4.35M
5.85M
Operating expense
5.00M
4.41M
4.35M
5.85M
Total operating expenses
3.20M
11.99M
16.51M
23.98M
Operating income
-3.20M
-11.99M
-16.51M
-23.98M
Other non operating income
-3.50M
-91.00K
615.00K
357.00K
EBT including unusual items
-14.65M
-12.27M
-16.23M
-24.01M
EBT excluding unusual items
-6.75M
-12.27M
-16.23M
-24.01M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.65M
-12.27M
-16.23M
-24.01M
Net profit margin
-
-
-
-
Earnings per share
-9.58
-8.94
-6.68
-8.51
Interest and investment income
-
486.00K
765.00K
819.00K
Interest expense
-46.00K
-674.00K
-1.10M
-1.20M
Net interest expenses
-46.00K
-188.00K
-332.00K
-382.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.20M
-11.74M
-15.88M
-23.24M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps